Compare GKOS & GLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | GLNG |
|---|---|---|
| Founded | 1998 | 1946 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.6B |
| IPO Year | 2015 | 2002 |
| Metric | GKOS | GLNG |
|---|---|---|
| Price | $102.43 | $49.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $126.92 | $50.63 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 04-29-2026 | 11-21-2023 |
| Dividend Yield | N/A | ★ 1.85% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.32 | $3.14 |
| Revenue Next Year | $27.43 | $8.66 |
| P/E Ratio | ★ N/A | $80.48 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $35.02 |
| 52 Week High | $148.11 | $57.79 |
| Indicator | GKOS | GLNG |
|---|---|---|
| Relative Strength Index (RSI) | 28.38 | 32.62 |
| Support Level | $92.38 | $38.79 |
| Resistance Level | $102.80 | $57.30 |
| Average True Range (ATR) | 7.36 | 1.65 |
| MACD | -4.94 | -0.91 |
| Stochastic Oscillator | 1.08 | 13.98 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Golar LNG Ltd designs, converts, owns, and operates marine infrastructure for the liquefaction of natural gas and provides floating liquefied natural gas (FLNG) services. It offers solutions for gas resource holders to develop and utilize gas reserves, including stranded, associated, flared, or underutilized resources. The company's reportable segments are: i) FLNG: includes the operations of FLNG vessels and projects, and ii) Corporate and other: includes legacy shipping segment activities, vessel management, floating storage and regasification unit services for third parties. The majority of the company's revenue is derived from the FLNG segment. Geographically, it generates the maximum revenue from Cameroon.